81 reports

The primary outcome measure included percentage of participants with complete cytogenetic response (CCyR) at Year ##.

  • Lung Cancer
  • China
  • United States
  • Product Initiative
  • Athenex, Inc.

One cycle lasts ## days.

  • Lung Cancer
  • Japan
  • United States
  • World
  • Product Initiative
  • CYTOGENETICS RESPONDED, WITH A MEDIAN SURVIVAL OF 2.8 MONTHS.
  • CPI-613 - DRUG PROFILE

Among ## patients with poor-risk cytogenetics, the ORR was ## percent (## CR + ## CRi), with a median survival of ##. ## months.

  • Hepatitis
  • Lung Cancer
  • North America
  • United States
  • Merck & Co., Inc.

The majority of AEs were grade ##/ ##.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

The trial will include patients who have one or more cytogenetic abnormalities that predict poor prognosis and reduced responsiveness to current standard-of-care therapies, including deletion of chromosomes ##p or ##p, amplification of chromosome ##q, or the chromosomal translocation

  • Chemotherapy
  • Lung Cancer
  • Monoclonal Antibody
  • Therapy
  • Merck & Co., Inc.

The majority of AEs were grade ##/ ##.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

The trial will include patients who have one or more cytogenetic abnormalities that predict poor prognosis and reduced responsiveness to current standard-of-care therapies, including deletion of chromosomes ##p or ##p, amplification of chromosome ##q, or the chromosomal translocation

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

ITP is commonly observed in AML patients and may not be linked to treatment with AST-VAC## or any other therapies. cytogenetics.

  • Cancer
  • Immunotherapy
  • Lung Cancer
  • Therapy
  • Geron Corporation
  • BEMCENTINIB - DRUG PROFILE

All responders were above the age of ##, at least one had secondary disease, and two had unfavourable cytogenetic profiles.

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Exelixis, Inc.

Among AML patients (## denovo; ## secondary), ## percent had favorable, ## percent intermediate (int)-I, ## percent int-II and ## percent adverse cytogenetic abnormalities (## pt not assessed).

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Genentech, Inc.

The primary outcome measure included percentage of participants with complete cytogenetic response (CCyR) at Year ##.

  • Laboratory
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Blood Disease
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Incyte Corporation

Among ## patients with poor-risk cytogenetics, the ORR was ## percent (## CR + ## CRi), with a median survival of ##. ## months.

  • Clinical Trial
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

One cycle lasts ## days.

  • Lung Cancer
  • Musculoskeletal Disorder
  • United States
  • World
  • Product Initiative

Of ## evaluable pts achieving major cytogenetic response, ##% retained their response and are still on therapy; ## pts achieved complete response.

  • Colorectal Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative

The trial will include patients who have one or more cytogenetic abnormalities that predict poor prognosis and reduced responsiveness to current standard-of-care therapies, including deletion of chromosomes ##p or ##p, amplification of chromosome ##q, or the chromosomal translocation

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.
  • Australia or to extend the agreement with STA.

All pts were in CR after cy ##. ## of the ## (##%) with Ph+ metaphases achieved a CCyR after ## cy; ## had a minor cytogenetic response only and ## had no cytogenetic analysis at CR, both of them achieved a CCyR after cy ##.

  • Lung Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.

The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and cytogenetic analyses.

  • Cancer
  • Lung Cancer
  • Australia
  • North America
  • United States
  • INTEGRAGEN SA PIPELINE PRODUCTS AND ONGOING CLINICAL TRIALS OVERVIEW

The company offers services in the fields of pharmacogenetics, cytogenetics, epigenetics and agriculture.

  • Lung Cancer
  • France
  • United States
  • Company Financials
  • IntegraGen

The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and cytogenetic analyses.

  • Cancer
  • Lung Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

One CR patient achieved mCR and partial cytogenetic response after receiving four days of APR- ## monotherapy.

  • Lung Cancer
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative

The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and cytogenetic analyses.

  • Cancer
  • Chemotherapy
  • Lung Cancer
  • Therapy
  • United States

The trial will include patients who have one or more cytogenetic abnormalities that predict poor prognosis and reduced responsiveness to current standard-of-care therapies, including deletion of chromosomes ##p or ##p, amplification of chromosome ##q, or the chromosomal translocation

  • Cancer
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.

Patients will be randomized ##:##:## to one of three arms: CABOMETYX and Opdivo; CABOMETYX, Opdivo and Yervoy; or sunitinib.

  • Lung Cancer
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

The Philadelphia chromosome (Ph) is a cytogenetic abnormality that occurs in approximately ##% of adult ALL patients and a small percentage of pediatric ALL patients.

  • Breast Cancer
  • Epidemiology
  • Lung Cancer
  • Therapy
  • Product Initiative

Patients will be randomized ##:##:## to one of three arms: CABOMETYX and Opdivo; CABOMETYX, Opdivo and Yervoy; or sunitinib.

  • Immunotherapy
  • Lung Cancer
  • Monoclonal Antibody
  • Oncology
  • Bristol-Myers Squibb Company

FIVE OF THE ## PATIENTS HAD HIGH-RISK CYTOGENETICS INCLUDING DELETION OF CHROMOSOME ##P.

  • Lung Cancer
  • Lymphoma
  • North America
  • United States
  • Merck & Co., Inc.

THE SECONDARY OUTCOME MEASURES OF THE STUDY WERE DURATION OF MAJOR CYTOGENETIC RESPONSE (MCYR), COMPLETE HEMATOLOGIC RESPONSE (CHR) RATE ASSESSED BY A BLOOD TEST, COMPLETE CYTOGENETIC RESPONSE (CCYR) RATE ASSESSED BY BONE MARROW ASSESSMENT, OVERALL (COMPLETE/ PARTIAL/ MINOR

  • Cancer
  • Hospital
  • Lung Cancer
  • Therapy
  • Bristol-Myers Squibb Company

Five of the ## patients had high-risk cytogenetics including deletion of chromosome ##p.

  • Cancer
  • Lung Cancer
  • Therapy
  • United States
  • Merck & Co., Inc.

FRANZ KOHLER CHEMIE GMBH CYTACOAT AB ENDACEA INC ENLIVEX THERAPEUTICS LTD ENZYCHEM LIFESCIENCES CORP EUNOIA BIOTECH LLC EXOXEMIS INC EXPRESSION DRUG DESIGNS LLC GPN VACCINES PVT LTD HIBERNAID INC ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Blood Disease
  • Lung Cancer
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company